eccogene glp 1 Announces Positive Topline Results from Phase 1b Trial of Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, in Adult Participants Living with Obesity/Overweight, with or without Type 2 Diabetes in China Oral GLP-1 Market to Rise

Interest in phenolic acids has recently increased due to their potential protective effects, achieved through the consumption of fruits and vegetables, against oxidative damage-related diseases such as coronary heart disease, stroke, and certain cancers (Glin et al

Helping other antioxidants such as vitamin C and vitamin E to continue their antioxidant functions

The SELECT cardiovascular outcomes trial showed that semaglutide 2.4 mg significantly reduced major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) in patients with established cardiovascular disease and overweight or obesity, even without type 2 diabetes

Thats because a 500mg dose of powder amounts to 439mg of berberine, which doesnt exactly align with a clinical dose

Desde entonces se han realizado hallazgos similares en otras cohortes prospectivas

PRKN: Parkin